Binding and structure-kinetic relationship analysis of selective TLR4-targeted immunosuppressive self-assembling heparin nanoparticles-Reference-Cited by-同舟云学术

Binding and structure-kinetic relationship analysis of selective TLR4-targeted immunosuppressive self-assembling heparin nanoparticles

Published:2018-12 Issue:1-2 Volume:552 Page:76-83
ISSN:0378-5173
Container-title:International Journal of Pharmaceutics
language:en
Short-container-title:International Journal of Pharmaceutics

Author:

Babazada Hasan,Yanamoto Shinya,Hashida Mitsuru,Yamashita Fumiyoshi^ORCID

Funder

JSPS KAKENHI

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference31 articles.

1. Structural features of glycol-split low-molecular-weight heparins and their heparin lyase generated fragments;Alekseeva;Anal. Bioanal. Chem.,2014

2. Biological responses to materials;Anderson;Annu. Rev. Mater. Res.,2001

3. Designing biomaterials with immunomodulatory properties for tissue engineering and regenerative medicine;Andorko;Bioeng. Transl. Med.,2017

4. Suppression of experimental arthritis with self-assembling glycol-split heparin nanoparticles via inhibition of TLR4-NF-κB signaling;Babazada;J. Control. Release,2014

5. Self-assembling lipid modified glycol-split heparin nanoparticles suppress lipopolysaccharide-induced inflammation through TLR4–NF-κB signaling;Babazada;J. Control. Release,2014

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MicroRNA-630: A potential guardian against inflammation in diabetic kidney disease;World Journal of Diabetes;2024-09-15

2. Computational Simulations of Glycan Recognition by Lectins and Other Carbohydrate Binding Proteins;Comprehensive Computational Chemistry;2024

3. Engineered macromolecular Toll-like receptor agents and assemblies;Trends in Biotechnology;2023-09

4. Preparation, Anticoagulant and Antioxidant Properties of Glucosamine-Heparin Salt;Marine Drugs;2022-10-18

5. Nanocarriers in the Delivery of Hydroxychloroquine to the Respiratory System: An Alternative to COVID-19;Current Drug Delivery;2021-08-06